MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering
MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company, announced the pricing of an underwritten offering of 7,142,857 Class A ordinary shares at $10.50 per share.
The gross proceeds from the offering are expected to be approximately $75 million, before deducting underwriting discounts and commissions.
The offering is expected to close on or about November 6, 2025, subject to customary closing conditions.
All of the securities to be sold in the offering are being offered by MoonLake.
MoonLake is focused on advancing therapies to address significant unmet needs in inflammatory skin and joint diseases.
Author's summary: MoonLake Immunotherapeutics raises $75 million.